Bel­gian VC be­hind Ab­b­Vie-owned Syn­de­si clos­es sec­ond in­vest­ment fund, se­cur­ing nine-fig­ure raise

Since start­ing up in 2015, a Bel­gian VC has been in­volved in back­ing sev­er­al biotechs — with one that has al­ready gone on to a buy­out. That biotech was Syn­de­si, which just got picked up by Ab­b­Vie ear­li­er this month for up to $1 bil­lion in a back­end-heavy deal.

Less than a month af­ter the Syn­de­si ac­qui­si­tion and two weeks af­ter ra­dio­phar­ma R&D up­start Pre­cir­ix net­ted $88 mil­lion in a Se­ries B, the VC, V-Bio Ven­tures, now has more mon­ey to work with. The VC an­nounced ear­ly Thurs­day that it has of­fi­cial­ly closed its sec­ond in­vest­ment fund, apt­ly named V-Bio Fund 2.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER